La Jolla, CA – According to filings with the U.S. Securities and Exchange Commission, MatriSys Bioscience is raising $61,748,311.00 in new funding. Sources indicate as part of senior management President, Philippe Calais played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MatriSys Bioscience
MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company focused on the $142 Billion WW dermatology and skin care market. We are developing therapies for the top 5 dermatology & skin care conditions – Atopic Dermatitis, Rosacea, Psoriasis, Acne, and Skin Infections, which have a huge impact on quality of life. More than 230 million patients suffer from these 5 skin diseases, which represent a $12.9 Billion Rx market and a $121 Billion skin care market. Our lead microbiome Phase I/II clinical program addresses the Atopic Dermatitis (AD) market with 15 M US patients (132 M worldwide), is NIH funded, and IP protected with an exclusive license from UCSD. Our Good Bug, S. hominis, is highly potent against the Bad Bug, Staphaureus, which has long been associated with ADS hominis does not affect other Good Bugs leading to the natural rebalance of the skin microbiome.

To learn more about MatriSys Bioscience, visit http://www.matrisysbio.com/

Contact:
Philippe Calais, President
619-633-2864
pcalais@matrisysbio.com
https://www.linkedin.com/in/philippe-calais-7106217/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved